Keros Therapeutics (KROS) CEO earns 62,500 options as half of 125,000 grant vests

Rhea-AI Filing Summary

Keros Therapeutics CEO Jasbir Seehra reported a performance-based stock option update. On January 7, 2026, he was credited with 62,500 employee stock options with an exercise price of $63.61 per share, following certification of performance conditions by the board’s compensation committee.

The original grant, reported in February 2024, covered options for 125,000 shares subject to performance goals. The committee determined that targets tied to 62,500 shares were achieved, causing 31,250 shares to vest immediately and scheduling another 31,250 to vest on December 31, 2026, if he remains in continuous service through that date. Performance conditions tied to the remaining 62,500 shares were not met, and that portion of the option was forfeited for no consideration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seehra Jasbir

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$63.61	01/07/2026		A		62,500		(1)	02/22/2034	Common Stock	62,500	$0	62,500	D

Explanation of Responses:

1. On February 23, 2024, the Reporting Person filed a Form 4 with the SEC reporting the grant of an option to purchase 125,000 shares of common stock, the vesting of which was subject to the achievement of specified performance criteria. On January 7, 2026, the Compensation Committee of the Issuer's Board of Directors certified that (i) certain performance condition with respect to the option to purchase 62,500 shares had been met, resulting in the immediate vesting of 31,250 shares and the vesting of 31,250 shares on December 31, 2026, subject to the continuous service of the Reporting Person through such date, and (ii) certain performance condition with respect to the option to purchase 62,500 shares had not been met, resulting in the forfeiture of such option for no consideration.

	/s/ Keith Regnante, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Keros Therapeutics (KROS) report for January 7, 2026?

The filing shows CEO and director Jasbir Seehra was credited with 62,500 employee stock options on January 7, 2026, following certification of performance conditions related to a prior grant.

What are the key terms of Jasbir Seehras new Keros (KROS) stock options?

The derivative security is an Employee Stock Option (right to buy) with an exercise price of $63.61 per share, covering 62,500 shares of Keros Therapeutics common stock.

How do the performance conditions affect the vesting of KROS CEO Jasbir Seehras options?

The compensation committee certified that performance conditions for an option on 62,500 shares were met, causing 31,250 shares to vest immediately and another 31,250 to vest on December 31, 2026, contingent on continuous service.

What happened to the remaining performance-based options in the KROS CEO grant?

Performance conditions tied to an additional 62,500-share portion of the original 125,000-share option grant were not met, and that portion of the option was forfeited for no consideration.

How many Keros (KROS) derivative securities does Jasbir Seehra hold after this transaction?

Following the reported transaction, 62,500 derivative securities (stock options) are shown as beneficially owned, held with direct ownership status.

Was this Keros (KROS) Form 4 transaction made under a Rule 10b5-1 trading plan?

The form includes a checkbox for trades under a Rule 10b5-1(c) plan, but the provided excerpt does not indicate that this box was checked as part of the reported option vesting and forfeiture.